There are 412 resources available
675P - A phase I study of safety, pharmacokinetics, and pharmacodynamics of SCR-6920, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced malignant tumors
Presenter: Jinming Yu
Session: Poster session 17
85P - In silico evaluation of the transcriptomic and immunologic profile of lung adenocarcinomas with deletions or disruptive mutations of SMARCA4
Presenter: Ester Garcia Lorenzo
Session: Poster session 09
1067P - The interchangeability of Immune checkpoint inhibitors
Presenter: Lonneke Timmers
Session: Poster session 19
1369P - BrigAlec study: Focus on alectinib efficacy after brigatinib exposure in BrigALK2 study (GFPC 02-2019)
Presenter: Renaud Descourt
Session: Poster session 20
1404P - Clinical characteristics and therapeutics sequences of KRAS G12C metastatic non-small cell lung cancer (mNCSLC) patients treated by sotorasib in the French pre-marketing authorization (MA) early access program (cohort temporary authorization of use, cATU)
Presenter: Herve Lena
Session: Poster session 20
1022MO - Predicting overall survival of patients with melanoma and NSCLC treated with immunotherapy using AI combining total tumor volume and tumor heterogeneity on CT-Scans
Presenter: Lama Dawi
Session: Mini oral session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
220P - Biomarker of blood age and inflammation in older cancer patients might predict outcome
Presenter: Marcus Vetter
Session: Poster session 01